CN103338791A - 放射性示踪剂组合物 - Google Patents

放射性示踪剂组合物 Download PDF

Info

Publication number
CN103338791A
CN103338791A CN2011800590925A CN201180059092A CN103338791A CN 103338791 A CN103338791 A CN 103338791A CN 2011800590925 A CN2011800590925 A CN 2011800590925A CN 201180059092 A CN201180059092 A CN 201180059092A CN 103338791 A CN103338791 A CN 103338791A
Authority
CN
China
Prior art keywords
compositions
formula
btm
peptide
targeting moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800590925A
Other languages
English (en)
Chinese (zh)
Inventor
T.恩格尔
J.格里希
D.曼齐拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to CN201711237827.4A priority Critical patent/CN107753962A/zh
Publication of CN103338791A publication Critical patent/CN103338791A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2011800590925A 2010-12-09 2011-12-09 放射性示踪剂组合物 Pending CN103338791A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711237827.4A CN107753962A (zh) 2010-12-09 2011-12-09 放射性示踪剂组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42139010P 2010-12-09 2010-12-09
US61/421,390 2010-12-09
PCT/EP2011/072352 WO2012076697A1 (en) 2010-12-09 2011-12-09 Radiotracer compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711237827.4A Division CN107753962A (zh) 2010-12-09 2011-12-09 放射性示踪剂组合物

Publications (1)

Publication Number Publication Date
CN103338791A true CN103338791A (zh) 2013-10-02

Family

ID=45346469

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800590925A Pending CN103338791A (zh) 2010-12-09 2011-12-09 放射性示踪剂组合物
CN201711237827.4A Pending CN107753962A (zh) 2010-12-09 2011-12-09 放射性示踪剂组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711237827.4A Pending CN107753962A (zh) 2010-12-09 2011-12-09 放射性示踪剂组合物

Country Status (7)

Country Link
US (2) US9180213B2 (cg-RX-API-DMAC7.html)
EP (1) EP2648767B1 (cg-RX-API-DMAC7.html)
JP (1) JP6055417B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130124522A (cg-RX-API-DMAC7.html)
CN (2) CN103338791A (cg-RX-API-DMAC7.html)
CA (1) CA2820387A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012076697A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999603A (zh) * 2014-12-04 2017-08-01 通用电气健康护理有限公司 从放射性药物中除去乙醛的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
US9550704B2 (en) * 2012-05-24 2017-01-24 Futurechem Co., Ltd. Method for synthesizing radiopharmaceuticals using a cartridge
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151054A (zh) * 2004-09-14 2008-03-26 通用电气医疗集团股份有限公司 放射性氟化肽
WO2010079079A2 (en) * 2008-12-17 2010-07-15 General Electric Company PDGF-Rβ BINDERS
WO2010114723A1 (en) * 2009-03-30 2010-10-07 Ge Healthcare Limited Radiolabelling reagents and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
US7659400B2 (en) * 2003-07-31 2010-02-09 Washington University Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging
JP2009508090A (ja) 2005-08-31 2009-02-26 イムノメディクス, インコーポレイテッド 予め標的化されたポジトロン放出断層撮影画像化のためのf−18ペプチド
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20080318577A1 (en) 2007-06-25 2008-12-25 Interdigital Technology Corporation Method and apparatus for supporting inter-frequency and inter-radio access technology handover
JP2011526267A (ja) 2008-07-03 2011-10-06 バイエル ファーマ アクチエンゲゼルシャフト 化合物および放射性医薬品の製造方法
EP2322500A1 (en) * 2009-11-11 2011-05-18 Bayer Schering Pharma Aktiengesellschaft Fluoro-labeled homo-glutamate derivatives and precursors thereof
CA2780930A1 (en) * 2009-11-17 2011-05-26 Mathias Berndt Method for production of f-18 labeled glutamic acid derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151054A (zh) * 2004-09-14 2008-03-26 通用电气医疗集团股份有限公司 放射性氟化肽
WO2010079079A2 (en) * 2008-12-17 2010-07-15 General Electric Company PDGF-Rβ BINDERS
WO2010114723A1 (en) * 2009-03-30 2010-10-07 Ge Healthcare Limited Radiolabelling reagents and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THORSTEN POETHKO,ET AL.: "Two-Step Methodology for High-Yield Routine Radiohalogenation of Peptides: 18F-Labeled RGD and Octreotide Analogs", 《THE JOURNAL OF NUCLEAR MEDICINE》, vol. 45, no. 5, 31 May 2004 (2004-05-31), pages 892 - 902 *
XUEHE LI, ET AL.: "Site-Specific Labeling of Annexin V with F-18 for Apoptosis Imaging", 《BIOCONJUGATE CHEM.》, vol. 19, no. 8, 16 July 2008 (2008-07-16), XP026878300 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999603A (zh) * 2014-12-04 2017-08-01 通用电气健康护理有限公司 从放射性药物中除去乙醛的方法
CN106999603B (zh) * 2014-12-04 2022-05-27 通用电气健康护理有限公司 从放射性药物中除去乙醛的方法

Also Published As

Publication number Publication date
EP2648767A1 (en) 2013-10-16
WO2012076697A1 (en) 2012-06-14
JP6055417B2 (ja) 2016-12-27
EP2648767B1 (en) 2023-03-15
US9180213B2 (en) 2015-11-10
CN107753962A (zh) 2018-03-06
US20130259804A1 (en) 2013-10-03
US9987382B2 (en) 2018-06-05
JP2014500268A (ja) 2014-01-09
US20160022847A1 (en) 2016-01-28
KR20130124522A (ko) 2013-11-14
CA2820387A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
JP5860808B2 (ja) 放射性ヨウ素化方法
CN103153350B (zh) 肽放射性示踪剂组合物
US9987382B2 (en) Radiotracer compositions
CN103228298A (zh) 凋亡pet成像剂
JP6244342B2 (ja) ヨウ素放射性標識法
CN105848687A (zh) 放射性示踪剂组合物和方法
US20130209358A1 (en) Radiotracer compositions
US20150139902A1 (en) Purification of [18f] - fluciclatide
CN103269725A (zh) 放射性缀合法
US20160303262A1 (en) Purification method and compositions
JP2015504875A (ja) 放射性フッ素化方法
AU2013351327A1 (en) 18F-labelled aldehyde compositions for radiofluorination
ES2643230T3 (es) Método de radioyodación
CN105339013A (zh) 金属络合物及其氟化
US20130315824A1 (en) Radioiodination method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131002